

April 7, 2020

Listing Department
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai – 400001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400051

Code: CADILAHC

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a Press Release dated April 7, 2020 titled “Zydus receives final approval from USFDA for Perphenazine Tablets USP”.

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors’ at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

sd/-

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zy+us receives final approval from USFDA for Perphenazine Tablets USP

Ahmedabad, April 7, 2020

Zy+us Cadila has received final approval from the USFDA to market Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg. (US RLD: Trilafon® Tablets)

This medication is indicated for the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. The drug will be manufactured at the group's formulation manufacturing facility at Baddi.

The group now has 284 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

About Zy+us Cadila

Zy+us Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zy+us aspires to be a research-based pharmaceutical company by 2020.
